Moberg Pharma AB (publ) (MOB.ST)
| Previous close | 28.04 |
| Open | 28.04 |
| Bid | 26.38 x 0 |
| Ask | 26.50 x 0 |
| Day's range | 26.02 - 28.26 |
| 52-week range | 4.13 - 40.90 |
| Volume | |
| Avg. volume | 640,653 |
| Market cap | 768.465M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 04 Nov 2019 |
| 1y target est | 24.50 |
PR NewswireMOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication
Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.
- PR Newswire
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America
Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S.. Topline results are expected in January 2025.
PR NewswireMOB-015 is recommended for approval in EU: Moberg Pharma
Moberg Pharma AB (OMX: MOB) hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.
